ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Portfolio Pulse from
ARS Pharmaceuticals has announced that its product, neffy® (Epinephrine Nasal Spray), is now available on Express Scripts Commercial National Formularies as of November 22, 2024. This inclusion expands access for patients and caregivers managing Type 1 Allergic Reactions.
December 19, 2024 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ARS Pharmaceuticals' neffy® is now included in Express Scripts Commercial National Formularies, effective November 22, 2024, enhancing access for patients with Type 1 Allergic Reactions.
The inclusion of neffy® in Express Scripts' formularies is a significant development for ARS Pharmaceuticals, as it increases the product's accessibility to a broader patient base. This is likely to positively impact SPRY's stock price in the short term due to the potential increase in sales and market reach.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90